A Quality by Design approach to de-risk biosimilar development Biosimilar drugs have become a mainstay of modern medicine with the latest reports stating the global market could reach $55 billion by 2020. The ever evolving landscape has led to different approaches to biosimilar development over the years. Many sponsors now prefer a linear, orthogonal approach More
Improve speed to clinic and mitigate risk with appropriate analytical analysis View webinar here.
Demonstrating fingerprint-like similarity View webinar here.
Cutting edge insight into the challenges of Biosimilar comparability studies View webinar here.